© 2020 MJH Life Sciences and Urology Times. All rights reserved.
Genitourinary Cancers
Atezolizumab shows similar efficacy in upper tract urothelial carcinoma and standard bladder cancer
June 19, 2020
Median overall survival is the same for both malignancies, study results show.
Prostate Ca assay appears similarly predictive of adverse pathology in African American, Caucasian patients
June 15, 2020
In this video, Eric Klein, MD, discusses a study evaluating the 17-gene Oncotype DX Genomic Prostate Score assay in African American and Caucasian American men.
Research confirms prognostic performance of genomic classifier
June 10, 2020
The classifier can be a useful adjunct for clinical decision-making, an investigator says.
Is a reduced bacillus Calmette-Guérin regimen feasible?
June 02, 2020
"In the era of BCG shortage, it would have been highly desirable to demonstrate the efficacy and safety of fewer BCG instillations for high-risk bladder cancer. However, reduced frequency of maintenance BCG instillations is associated with increased risk of cancer recurrence, albeit with fewer adverse effects," writes Badar M. Mian, MD.
Robotics in GU oncology: Current status, future directions
May 22, 2020
The breadth of applications will widen as the number of new platforms grows, according Joshua Calvert, MD, MPH.
Operationalizing immunotherapy in urologic practice
May 22, 2020
A team-based approach is key to safely and appropriately dispensing checkpoint inhibitors, according to Gautam Jayram, MD.
FDA approves 2 PARP inhibitors for certain men with prostate cancer
May 21, 2020
The FDA has approved 2 poly (ADP-ribose) polymerase (PARP) inhibitors for men with metastatic castration-resistant prostate cancer who have certain genetic mutations, marking the first approvals of this newer drug class in prostate cancer.
Management of UTUC using a kidney-sparing approach
May 21, 2020
Advances in endourology have made kidney-sparing treatments a viable treatment option.
Dr. Angela Smith discusses the recent FDA approval of Jelmyto for low-grade UTUC
May 20, 2020
The FDA recently granted approval for Jelmyto, which is the first therapy for the treatment of low-grade upper tract urothelial cancer. Urology Times® spoke with Angela B. Smith, MD, MS, regarding the significance of this approval for providers and patients.
Further Evaluation of Tivozanib Shows Promise for Relapsed, Refractory Renal Cell Carcinoma
May 19, 2020
Results from the phase III TIVO-3 trial of tivozanib (Fotivda) demonstrated a statistically significant improvement in median progression-free survival compared with sorafenib (Sutent), as well as favorable tolerability, in patients with relapsed or refractory renal cell carcinoma.